Craif Launches Follow Up Study to Further Improve the Performance of miSignal™

 Craif Inc. (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”) started a follow-up study to further improve the performance of its cancer screening test, miSignal™.

■ Outline of the study
 Since its release in February 2022, miSignal™ has been researched and developed1), 2) as a new screening test for cancer, which has been introduced and used at many hospitals. It is expected that its performance can be further improved by conducting a study taking the results of other medical checkups into consideration. In this study, we will estimate the performance of miSignal™ in the real world and aim to further improve the performance of the test by conducting a follow-up study with its examinees.

■ Outline of miSignal™
 miSignal™ is a PCR test that detects urinary miRNA which plays an important role in the onset, progression and metastasis of cancer. Our distinctive technology efficiently captures urinary miRNA and detects the risk of early-stage cancer with high accuracy. The greatest feature of this test is that it is “painless.” By simply submitting urine to a medical institution, you can easily check your risk of cancer without any burden. The first test from miSignal™ series will be for ovarian cancer available from 1st February 2022. Along with the progress of R&D, the number of cancer types that miSignal can cover will gradually increase.

1) Yasui, T. et al. (2017) Unveiling Massive Numbers of Cancer-related Urinary-microRNA Candidates via Nanowires. Sci Adv. (2017) 3: e1701133
2) Take, S. et al., (2021) Urinary MicroRNAs as Biomarkers for Early Detection of Ovarian Cancer. European Society for Medical Oncology (ESMO) congress.